CAMBRIDGE, MA – April 27th, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today that clinical trial investigator, Alexander I Spira, MD, PhD, FACP, Co-Director of the Virginia Cancer Specialists (VCS) Research Institute and Director of the Thoracic and Phase I Program, will present a Trials in Progress Poster for HFB200301 on Sunday, June 5 from 8:00 AM to 11:00 AM CT at the 2022 ASCO Annual Meeting held June 3 – 7, 2022, in Chicago, IL.
“HFB200301 is an anti-TNFR2 antibody that induces T cell and natural killer cell activation, demonstrated in preclinical models. The unique mechanism of action indicates that HFB200301 functions as a bridge between innate and adaptive immunity” said Dr. Alexander Spira. “We are excited to have VCS medical staff and patients to be a part of this Phase I clinical study (NCT05238883). Our hospital’s clinical strength combined with HiFiBiO’s innovative DIS® approach will hopefully accelerate the clinical development of HFB200301 for cancer patients.”
“We look forward to sharing the clinical study for HFB200301, a first-in-class cancer therapeutic targeting TNFR2 as well as our DIS® indications selection strategy,” said Luigi Manenti, MD, Chief Medical Officer of HiFiBiO Therapeutics. “With strong in-vivo efficacy as a monotherapy and in combination with anti-PD-1 in preclinical models, we believe it has significant potential in DIS® selected tumor types including EBV+ gastric cancer, PD-L1+ pleural mesothelioma and clear cell renal cell carcinoma.”
Details on the poster presentation are as follows:
Title: Phase I study of HFB200301, a first-in-class TNFR2 agonist monoclonal antibody in patients with solid tumors selected via Drug Intelligent Science (DIS®)
Abstract Number: TPS2670
Poster Session: Developmental Therapeutics – Immunotherapy
Session Date and Time: Poster Session 3 – Sunday, June 5 at 8:00 AM – 11:00 AM CT
The abstract will be available through the ASCO Meeting Library at https://meetinglibrary.asco.org/ on May 26, 2022.
HFB200301 is a first-in-class agonistic anti-TNFR2 antibody that binds potently and selectively to TNFR2 and induces the activation of CD4 T cells, CD8 T cells and NK cells. In vivo, HFB200301 demonstrates potent antitumor activity as a single agent and in combination with anti-PD-1. HiFiBiO is applying a biomarker strategy by leveraging its DIS® platform to select indications who may benefit the most from HFB200301 treatment.
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is a clinical stage biotech company advancing a robust pipeline targeting both the innate and adaptive immunity to treat cancer and autoimmune disease. Our proprietary and versatile DIS® single-cell platform enables the rapid discovery of novel antibody therapeutics with predictive biomarkers through our internal development programs and strategic collaborations. Our passionate team across three continents embraces a fast-paced and engaging work environment to bring transformative medicines to patients. www.hifibio.com
HiFiBiO® and DIS® are trademarks of HiFiBiO and its affiliates.